These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 35820135)

  • 1. The Role of Compounding Pharmacists During Drug Shortages.
    Ofei K
    Int J Pharm Compd; 2022; 26(4):298-301. PubMed ID: 35820135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allowing Compounding Pharmacies to Address Drug Shortages.
    Broughel J
    Int J Pharm Compd; 2022; 26(2):100-109. PubMed ID: 35413008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance.
    Greeson NM; Mixon W; Allan WC
    Int J Pharm Compd; 2020; 24(5):371-379. PubMed ID: 32886634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Managing the COVID-19 health crisis: a survey of Swiss hospital pharmacies.
    Schumacher L; Dhif Y; Bonnabry P; Widmer N
    BMC Health Serv Res; 2023 Oct; 23(1):1134. PubMed ID: 37864155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Shortages Prior to and During the COVID-19 Pandemic.
    Callaway Kim K; Rothenberger SD; Tadrous M; Hernandez I; Gellad WF; Devine JW; Hershey TB; Maillart LM; Suda KJ
    JAMA Netw Open; 2024 Apr; 7(4):e244246. PubMed ID: 38578641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 and Drug Shortages: A Call to Action.
    Shuman AG; Fox ER; Unguru Y
    J Manag Care Spec Pharm; 2020 Aug; 26(8):945-947. PubMed ID: 32715960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing between compounding facilities and the development of the 503B bulk drug substance list.
    Gianturco SL; Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e8-e11. PubMed ID: 32713748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transformational strategies for optimizing use of medications and related therapies through us pharmacists and pharmacies: Findings from a national study.
    Thornewill J; Antimisiaris D; Ezekekwu E; Esterhay R
    J Am Pharm Assoc (2003); 2022; 62(2):450-460. PubMed ID: 34758925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical compounding or pharmaceutical manufacturing? A regulatory perspective.
    Timko RJ; Crooker PE
    Int J Pharm Compd; 2014; 18(2):101-11. PubMed ID: 24881112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of outsourcing facilities in overcoming drug shortages.
    Mattingly AN
    J Am Pharm Assoc (2003); 2021; 61(1):e110-e114. PubMed ID: 32943335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic pharmacy leadership during the COVID-19 crisis: Optimizing patient care through formulary and drug shortage management.
    Pulk RA; Leber M; Tran L; Ammar M; Amin N; Miller L; Yazdi M
    Am J Health Syst Pharm; 2020 Oct; 77(22):1874-1884. PubMed ID: 32710774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.
    AlKhatib HS; Jalouqa S; Maraqa N; Ratka A; Elayeh E; Al Muhaissen S
    BMC Health Serv Res; 2019 Nov; 19(1):816. PubMed ID: 31703672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compounding pharmacies: before and after an inspection.
    Kulkarni D; Ricketts S
    Int J Pharm Compd; 2013; 17(5):358-62. PubMed ID: 24459779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. History of sterile compounding in U.S. hospitals: learning from the tragic lessons of the past.
    Myers CE
    Am J Health Syst Pharm; 2013 Aug; 70(16):1414-27. PubMed ID: 23903480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacy Emergency Preparedness and Response (PEPR): a proposed framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond.
    Aruru M; Truong HA; Clark S
    Res Social Adm Pharm; 2021 Jan; 17(1):1967-1977. PubMed ID: 32389631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients.
    Allen LV
    Int J Pharm Compd; 2023; 27(6):474-481. PubMed ID: 38100665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing Pharmacists to Optimize Medication Management Strategies During the COVID-19 Pandemic.
    Burgess LH; Cooper MK; Wiggins EH; Miller KM; Murray E; Harris S; Kramer JS
    J Pharm Pract; 2022 Apr; 35(2):184-189. PubMed ID: 33016180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceutical management of the COVID-19 pandemic in a mid-size hospital.
    Corregidor-Luna L; Hidalgo-Correas FJ; García-Díaz B
    Farm Hosp; 2020 Jun; 44(7):11-16. PubMed ID: 32533662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacy administration and pharmaceutical care practice in a module hospital during the COVID-19 epidemic.
    Hua X; Gu M; Zeng F; Hu H; Zhou T; Zhang Y; Shi C
    J Am Pharm Assoc (2003); 2020; 60(3):431-438.e1. PubMed ID: 32336673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.